Orbach Daniel, Brisse Hervé, Helfre Sylvie, Klijanienko Jerzy, Bours Danielle, Mosseri Véronique, Rodriguez José
Pediatric Oncology Department, Institut Curie, Paris, France.
Pediatr Blood Cancer. 2008 Apr;50(4):849-53. doi: 10.1002/pbc.21372.
To retrospectively report the clinical and therapeutic features of children with nasopharyngeal carcinoma (NPC) treated by chemotherapy and doses adapted of radiotherapy.
From 1978 to 2005, 34 children were treated for NPC. All histologic and/or cytologic samples and CT scans were reviewed. Cervical nodal irradiation was reduced (<50 Gy) in the case of a good response to chemotherapy (>/=90% of initial tumor volume).
Thirty-two children had metastatic cervical nodes and one child had systemic metastases at diagnosis. All children had AJJC-TNM Stage IV. Thirty-one children received neoadjuvant chemotherapy with various regimens. The overall chemotherapy response rate was 78%. Fifteen patients had cervical nodal irradiation dose reduced: Median 47 Gy (range: 45-50). Nasopharyngeal radiotherapy was delivered at a dose of 59.4 Gy (range: 45-66). Local and distant failure rates were 10% and 18%, respectively. The 5-year overall survival was 73 +/- 8% and the event-free survival (EFS) was 75 +/- 8%.
The overall prognosis was not influenced by TNM status, dose of local radiotherapy delivered or response to initial chemotherapy, but EFS was better in patients with a good response to chemotherapy. The cervical local failure rate was low despite radiotherapy dose reduction in the case of a good response to neoadjuvant chemotherapy. We also propose a reduction of nasopharyngeal radiation (</=50 Gy) in the case of good response to initial chemotherapy.
回顾性报告接受化疗及放疗剂量调整的儿童鼻咽癌(NPC)患者的临床及治疗特征。
1978年至2005年期间,34例儿童接受了NPC治疗。对所有组织学和/或细胞学样本及CT扫描进行了复查。若化疗反应良好(初始肿瘤体积缩小≥90%),则减少颈部淋巴结照射剂量(<50 Gy)。
32例儿童在诊断时有颈部淋巴结转移,1例儿童有全身转移。所有儿童均为AJJC-TNM Ⅳ期。31例儿童接受了不同方案的新辅助化疗。总体化疗反应率为78%。15例患者颈部淋巴结照射剂量减少:中位剂量47 Gy(范围:45 - 50 Gy)。鼻咽癌放疗剂量为59.4 Gy(范围:45 - 66 Gy)。局部和远处失败率分别为10%和18%。5年总生存率为73±8% ,无事件生存率(EFS)为75±8%。
总体预后不受TNM分期、局部放疗剂量或初始化疗反应的影响,但化疗反应良好的患者EFS更佳。在新辅助化疗反应良好的情况下,尽管放疗剂量减少,颈部局部失败率仍较低。我们还建议在初始化疗反应良好的情况下减少鼻咽癌放疗剂量(≤50 Gy)。